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Reticulocyte hemoglobin content (CHr) and percentage of hypochromic cells (%Hypo) are restricted to the Siemens analysers.
The aims of the study were to investigate the correlation of Red cells size factor (RSf) and low Hemoglobin density (LHD%),
reported by Beckman-Coulter analysers, with CHr and %Hypo in the assessment of iron status in the presence of inﬂammation.
381 samples were run on both LH 750 (Beckman-Coulter) and Advia 2120 (Siemens) analysers. Correlation between parameters
were calculated and the diagnostic performance of the new parameters was assessed. Results. Correlation between RSf and CHr,
r = 0.85. ROC curve analysis for RSf in the diagnosis of iron restricted erythropoiesis deﬁned as CHr < 28 pg: AUC 0.983;
Cutoﬀ 91.1%; Sensitivity 98.8%; Speciﬁcity 89.6% Correlation between LHD% and %Hypo, r = 0.869. ROC curve analysis for
LHD% in the diagnosis of iron deﬁciency deﬁned by %Hypo > 5%: AUC 0.954; Cut oﬀ 6.0%; Sensitivity 96.6%; Speciﬁcity 83.2%
Conclusions. RSf and LHD% could be reliable parameters for the study of iron metabolism status.
1.Introduction
In iron deﬁciency anemia (IDA) iron supply depends on the
quantity of iron storage in the body, while in functional iron
deﬁciency (iron restricted erythropoiesis) supply depends on
the rate of mobilization of iron from the stores. Functional
iron deﬁciency is deﬁned as an imbalance between the
iron needs for erythropoiesis and the iron supply, with
the latter not maintained at suﬃcient rate for adequate
hemoglobinization of reticulocytes and mature erythrocytes
[1].
The diagnosis of iron deﬁciency or functional iron
deﬁciency is particularly challenging in patients with acute
or chronic inﬂammatory conditions because most of the
biochemical markers for iron metabolism are aﬀected by
acutephasereaction.Thisisthecaseoftheanemiaofchronic
disease (ACD) and the anemia associated to chronic renal
failure (CKD).
Serum ferritin, an indicator of iron storage but not
of iron supply, is a positive acute phase reactant, while
transferrin is a negative acute phase reactant, rendering the
calculation of transferrin saturation unreliable in this case
[2–4].
For these reasons, an iron deﬁcient erythropoiesis may
occur despite that normal serum ferritin and transferrin
saturation values and interest have been generated in the use
of erythrocyte and reticulocyte parameters, available on the
modern analysers based on ﬂow cytometry technology.
Direct consequence of an imbalance between the ery-
throid marrow iron requirements and the actual supply is
a reduction of red cell hemoglobin content, which causes
h y p o c h r o m i cm a t u r er e dc e l l sa n dr e t i c u l o c y t e s .
Reticulocyte hemoglobin content (CHr) and the per-
centage of hypochromic red blood cells (%Hypo) reﬂect
iron availability and are reliable markers of functional iron
deﬁciency [5, 6].
The measurement of CHr is a direct assessment of the
incorporation of iron into erythrocyte hemoglobin (Hb) and
thus an estimate of the recent functional availability of iron
into the erythron; due to the life span of the reticulocytes,
CHr is a sensitive indicator of iron deﬁcient erythropoiesis
[7–9].2 Anemia
The measurement of %Hypo (deﬁned as the percentage
of red blood cells with Hb concentration less than 280g/L)
is a sensitive method for quantifying the hemoglobinization
of mature red cells. Because of the long circulating life span
of mature erythrocytes %Hypo values are related to iron
status in the last 2-3 months, and have been recognised as
an indicator of iron deﬁciency [10, 11].
CHr and %Hypo have been used as a diagnostic tool,
together with biochemical markers, to distinguish IDA from
ACD, and are incorporated to National Kidney Foundation
(NKF-K/DOQI) guidelines for the monitoring of recombi-
nant human erythropoietin rHuEPO therapy [12–14].
To date, the measurement of CHr and %Hypo has been
restricted to the analysers of a single manufacturer, Siemens
(Siemens Medical Solutions Diagnostics, Tarrytown N.Y,
USA). A second manufacturer has produced a comparable
index, the so-called reticulocyte hemoglobin equivalent (Ret
He) generated by the Sysmex XE 2100 analyser (Sysmex
Corporation, Kobe, Japan).
Measurements of Ret He provides useful information in
diagnosing anemia, iron restricted erythropoiesis, and func-
tional iron deﬁciency and response to iron therapy during
r-HuEPO. Twenty nine pg is the cutoﬀ value that deﬁnes
deﬁcient erythropoiesis [15, 16]. Ret He correlates with CHr
withthesameclinicalmeaning[17].ThenewSymexXE5000
analyser reports the percentages of hypochromic red cells,
but few data are already published about this parameter [18].
Beckman Coulter (Beckman Coulter Inc., Miami, Fl,
USA) has recently introduced on the LH series analysers two
new parameters
Red blood cell Size Factor (RSf) joins together the
volume of mature red cells (MCV) and the volume of
reticulocytes (MRV), both related to erythropoietic activity
and hemoglobinization
RSf =

MCV
∗MRV. (1)
Compared to the mature erythrocyte population, reticulo-
cytes have a mean volume 15–20fL greater, they stay in
the blood stream for 1–1.5 days, so the measurement of
reticulocyte number and cellular characteristics, such as
volume, provides real-time data regarding certain aspects of
erythropoiesis that can inﬂuence the dimensions of red cells,
such as iron availability. The examination of both precursors
and mature cells provides an opportunity to detect and
monitor acute and chronic changes in cellular hemoglobin
status, related to cell volume [19].
Low hemoglobin density (LHD%) derives from the
traditional mean cell hemoglobin concentration (MCHC),
using the mathematical sigmoid transformation
LHD% = 100
∗

1 −

1
(1+e1.8(30−MCHC))

. (2)
MCHC is an all-inclusive measure of both the availability
of iron over the preceding 90–120 days, and of the proper
introduction of iron into intracellular hemoglobin.
In the same way, LHD% is related to iron availability and
the hemoglobinization of the mature red cells.
In this equation deﬁning LHD%, in addition to the
standardsigmoidfunction,asquarerootisappliedtofurther
enhance numerical resolution in the region corresponding
to the lower end of %Hypo, to improve the diﬀerentiation
between the normal and the abnormal among the blood
samples having relatively low values of LHD% [20].
T h ea i m so ft h i ss t u d yw e r e
(i) toestablishthereferencerangeofRSfandLHD%and
their values in diﬀerent types of anemia;
(ii) to evaluate these recently introduced reticulocyte
and erythrocyte parameters provided by the LH
series analysers in terms of correlation with CHr
and %Hypo as well as their diagnostic eﬃciency
assuming CHr < 28.0pg or %Hypo > 5% to detect
iron restricted erythropoiesis and iron deﬁciency.
2.MaterialsandMethods
2.1. Criteria for Selecting the Groups of Patients. Samples
from 120 healthy individuals, 72 iron deﬁciency anemia
(IDA), 60IDA with acute phase response (IDA APR), 71
chronic kidney disease (CKD), and 58 anemia of chronic
disease (ACD) were randomly extracted from the routine
workload and run sequentially on both LH 750 (Beckman
Coulter Inc. Miami, Fl, USA) and Advia 2120 (Siemens Med-
ical Solutions Diagnostics, Tarrytown N.Y., USA), analysers
within 6 hours of collection.
Healthy group: 54 male and 66 female adult subjects,
with no clinical symptoms of disease and with results of
the complete blood count and biochemical iron metabolism
markers within reference ranges.
A group of 132IDA patients fulﬁlled traditional diagnos-
ticcriteriaforirondeﬁciencyanemiadiagnosis,serumiron<
7.5µmol/L, transferrin saturation < 20%, ferritin < 50µg/L,
and Hb < 110g/L, were included before iron treatment.
This group was divided into a nonacute phase response
group (n = 72, CRP < 5mg/L) and acute phase response
group (n = 60, CRP > 5mg/L). Acute phase response
included inﬂammation or infectious conditions, in addition
to ferropenic status.
CKDpatientsweremanagedaccordingtotherecommen-
dations of the NKF-K/DOQI guidelines [21]. All patients
were treated with a variety of erythropoietin doses, the
majority of them were treated with a maintenance dose of
intravenous iron weekly, in order to maintain Hb at the
recommended level 110–120g/L.
ACD group included patients with a variety of dis-
eases: chronic infections (tuberculosis); neoplasic disor-
ders (Hodgkin‘s disease, breast carcinoma); noninfectious
inﬂammatory diseases (rheumatoid arthritis, systemic lupus
erythematosus).
ACD patients received treatment to maintain normal
erythropoiesis and presented the traditional diagnostic cri-
teria for “Functional iron-deﬁciency” diagnosis Transferrin
saturation < 20%, Hb < 110g/L, and serum ferritin values
normal or over the reference range.
Table 1 shows the hematological and biochemical data of
the diﬀerent groups.Anemia 3
Table 1: Hematological and biochemical data of the healthy group (n = 120), iron deﬁciency anemia (IDA, n = 72), iron deﬁciency anemia
and acute phase response (IDA APR, n = 60), anemia of chronic disease (ACD, n = 58), and chronic kidney disease (CKD, n = 71) patients.
RBC 1012/L Hb g/L MCV fL MCH pg MCHC g/L Iron µmol/L Transf g/L Ferritin µg/L Sat %
Healthy mean 4.9 154 91.1 31.3 343 16.5 2.53 75 31
(SD) (0.27) (6.4) (2.55) (1.53) (5.2) 1(0.62) (0.2) (2.8) (1.9)
IDA mean 4.6 95 70 22.5 320 4.8 3.31 14 6
(SD) (0.61) (14.2) (10.3) (4.23) (17.3) (2.15) (0.53) (9) (3.6)
IDA APR mean 4.4 96 75.8 21.5 327 5.1 2.78 37 9
(SD) (0.43) (12.1) (3.7) (1.3) (9.2) (3.5) (0.28) (25) (5.6)
ACD mean 3.5 101 93.2 31.9 343 10.0 2.68 522 15
(SD) (0.48) (11) (6.0) (2.23) (10) (6.8) (0.66) (704) (5)
CKD mean 3.5 112 95.6 31.1 325 9.8 1.87 335 21
(SD) (0.45) (8.5) (6.67) (2.23) (8) (4.47) (0.43) (204) (10)
R B C ,r e db l o o dc e l l s ;H b ,h e m o g l o b i n ;M C V ,m e a nc e l lv o l u m e ;M C H ,m e a nc e l lh e m o g l o b i n ;M C H C ,m e a nc e l lh e m o g l o b i nc o n c e n t r a t i o n ;T r a n s f ,
transferrin; Sat, % transferrin saturation.
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Figure 1: Red blood cell size factor (RSf) values in a population of
120healthyadultsubjects.ThevaluesshowedGaussiandistribution
(Kolmogorov-Smirnoﬀ test, P = .279).
2.2. Statistical Evaluation of Analytical Results. Statistical
softwarepackageSPSS(SPSS;Chicago,IL,USA)version17.0
for Windows was applied for statistical analysis of the results.
Reference ranges were calculated from the results
obtained in the group of healthy subjects (95 central
percentiles of the distribution). Kolmogorov—Smirnoﬀ test
was applied to verify the Gaussian distribution of RSf and
LHD% values.
When the parameters under study presented a Gaus-
sian distribution correlation, coeﬃcients were calculated by
Pearson method; independent samples t-test was performed
in order to detect statistical deviations between the groups
of patients; P values less than .05 were considered to be
statistically signiﬁcant.
When the parameters under study presented a non-
Gaussian distribution correlation, coeﬃcients were calcu-
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Figure 2: Comparison of red blood cell size factor (RSf) in the
groups of anemic patients, anemia of chronic disease (ACD),
chronic kidney disease (CKD), iron deﬁciency anemia (IDA) iron
deﬁciency anemia and acute phase response (IDA APR), and in the
healthy group.
lated by Spearman method; independent samples Mann-
Whitney U-test was performed; P values less than .05 were
considered to be statistically signiﬁcant.
Receiver operating characteristic (ROC) curve analysis
was utilized to illustrate the diagnostic performance of RSf
and LHD% in the detection of iron deﬁciency status, deﬁned
by a CHr value 28pg.
Cutoﬀ values were established based on the optimal
combination of sensitivity and speciﬁcity.
3. Results
The values of RSf were normally distributed (P = .279)
(Figure 1). Reference range was 91.1–106.9fL.
Figure 2 and Table 2 exhibit CHr and RSf mean values
and standard deviation (SD) in the variety of anemia and
healthy subjects included in the study.
The horizontal line in the center of the box shows the
median value, the upper and lower limits of the box show the4 Anemia
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Figure 3: low hemoglobin density (LHD%) values in a population
of 120 healthy adult subjects. The values showed a non-Gaussian
distribution (Kolmogorov-Smirnoﬀ test, P = .034).
Table 2:Reticulocytehemoglobincontent(CHr)andredbloodcell
size factor (RSf) values, mean and standard deviation (SD), in the
group of patients.
CHr pgmean (SD) RSf fLmean (SD)
Healthy 33.2 (1.6) 100.9 (5.3)
IDA 24.5 (4.4) 88.1 (7.8)
IDA APR 25.6 (2.5) 84.7 (4.1)
ACD 30.8 (5.1) 105.5 (10.9)
CKD 31.6 (3.5) 110.6 (8.7)
interquartilerange,andthewhiskersshowtheminimumand
maximum values for each group.
The horizontal line in the center of the box shows the
median value, the upper and lower limits of the box show the
interquartilerange,andthewhiskersshowtheminimumand
maximum values for each group.
CorrelationbetweenCHrandRSfvalues,Pearsonregres-
sion coeﬃcient 0.85, P < .001.
Independent samples t-test was performed in order to
detect statistical deviations between the groups of patients.
Signiﬁcant diﬀerences in RSf mean values (P < .001)
were detected when groups with iron restricted erythro-
poiesis (IDA, mean 88.1fL and IDA with APR, mean 84.7fL)
were compared with patients undergoing therapy (ACD,
mean 108.9fL and CKD, 110.6fL) and the healthy subjects
(mean 100.9fL).
No statistic diﬀerence was found between IDA group and
IDA patients with acute phase response (P = .481).
IDA and IDA with APR groups presented iron restricted
erythropoiesisasisstatedbyCHrvalues(24.5pgand25.6pg,
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Figure 4: Comparison of low hemoglobin density (LHD%) in
the groups of anemic patients, anemia of chronic disease (ACD),
chronic kidney disease (CKD), iron deﬁciency anemia (IDA) iron
deﬁciency anemia and acute phase response (IDA APR), and in the
healthy group.
Table 3: Percentage of hypochromic red cells (% Hypo) values,
mean and standard deviation (SD) and low hemoglobin density
(LHD%) values, median (5th–95th interquartiles, IQ) in the group
of patients.
% Hypo Mean (SD) LHD% Median (IQ)
Healthy 0.13 (0.15) 2.1 (0.9–4.1)
IDA 17.2 (17.4) 29.6 (7.5–76)
IDA APR 16.8 (15.5) 27.3 (8.3–71.2)
ACD 4.1 (4.4) 7.3 (5.1–30)
CKD 5.1 (6.7) 9.6 (5.6–27)
resp.) ACD and CKD patients receiving therapy maintained
CHr levels higher than the cutoﬀ value of 28pg.
ROC curve analysis for RSf in the diagnosis of restricted
erythropoiesis, deﬁned by CHr < 28pg, results were AUC
0.983, Cutoﬀ 91.1fL, sensitivity 98.8%, speciﬁcity 89.6%.
The values of LHD% were not normally distributed (P =
.034) (Figure 3). Reference range was 0%–4.4%.
Figure 4 and Table 3 exhibit %Hypo values, mean and
standarddeviation(SD)andLHD%values,medianand5th–
95th interquartiles, in the variety of anemias and healthy
subjects included in the study.
The horizontal line in the center of the box shows the
median value, the upper and lower limits of the box show the
interquartilerange,andthewhiskersshowtheminimumand
maximum values for each group.
Correlation between %Hypo and LHD% values, r =
0.869 (Spearman method) (P < .001). y = 1.338x +4 .40.
Independent samples U-test was performed in order to
detect statistical deviations between the groups of patients.
Signiﬁcant diﬀerences in LHD% values (P < .001) were
detected when groups with iron deﬁciency (IDA, mean
29.6%andIDAwithAPR,mean27.3%)werecomparedwith
patients undergoing therapy (ACD, mean 7.3%; CKD, mean
9.6%) and the healthy subjects (median 2.1%).Anemia 5
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Figure 5: Receiver operating characteristic (ROC) curves for red
bloodcellsizefactor(RSf),lowhemoglobindensity(LHD%),retic-
ulocyte hemoglobin content (CHr), percentage of hypochromic
red cells (% Hypo), mean cell hemoglobin (MCH) and mean cell
volume (MCV) in the diagnosis of iron deﬁciency, deﬁned by CHr
< 28pg.
No statistic diﬀerence was found between IDA group and
IDA patients with acute phase response (P = .578).
Receiver operating characteristic (ROC) curve analysis
for LHD% in the diagnosis of iron deﬁciency, deﬁned by
%Hypo > 5% AUC 0.954, cutoﬀ 6.0%, sensitivity 96.6%,
speciﬁcity 83.3%.
Discriminant eﬃciency of biochemical parameters and
classical erythrocyte indices:
mean cell hemoglobin (MCH), AUC 0.89; mean cell
volume, (MCV), AUC 0.822; serum ferritin, AUC 0.722;
serum iron, AUC 0.683 (Figure 5).
4. Discussion
Uncomplicated iron deﬁciency is not diﬃcult to diagnose
by means of the traditional laboratory tests. Biochemical
markers are reliable parameters to diagnose iron deﬁciency
in an uncomplicated clinical setting.
Serum ferritin, as a potent positive acute phase reactant
isoftenincreasedinACDandCKDpatients[22].Transferrin
saturation is less than 15% to 20% in iron deﬁciency, but
expression of serum transferrin is reported to be downreg-
ulated by inﬂammatory cytokines, so may not reliably reﬂect
irondeﬁciencywhenanemiaiscomplicatedbyinﬂammation
[23].
Eﬀorts have been made to evaluate some readily available
and relatively inexpensive laboratory parameters as indirect
markers of iron restricted erythropoiesis and iron availability
in a clinical context inﬂuenced by inﬂammation and acute
phase reaction.
The best combination of hematological indices for iron
deﬁciency is an increased percentage of hypochromic ery-
throcytes and a reduced hemoglobin content of reticulocytes
[24].
Measurements of reticulocyte hemoglobin content
(CHr) have been shown to provide useful information in
diagnosing functional iron deﬁciency during r-HuEPO
therapy [25, 26] and response to iron therapy [27, 28].
Recent studies conﬁrm the clinical reliability of mature
erythrocyteparameters,suchashypochromicredcells(Hypo
%), as markers of iron deﬁciency in hemodialysis patients
[29, 30].
Beckman Coulter (Beckman Coulter Inc. Miami, Fl,
USA) applies the Volume Conductivity Scatter technology to
this ﬁeld and new parameters are now available on the LH
series analysers.
The main purpose of the present study was to determine
the diagnostic performance of RSf and LHD% and to assess
whether the new parameters correlate with the existing
diagnostictestsCHrand%Hypoforrestrictederythropoiesis
and functional iron deﬁciency diagnosis.
Thisstudyshowsareasonablelevelofagreementbetween
RSf and CHr.
Despite the fact that CHr is a measurement of the
reticulocyte hemoglobin content and RSf is a measurement
of both mature red cells and reticulocyte size, a high
concordance between these parameters has been observed
and values of both parameters showed the same trend in the
diﬀerent groups.
In patients with iron restricted erythropoiesis, (IDA and
IDA APR) RSf values were lower than the reference range
91.1fL.
ACD and CKD patients were receiving therapy, they
suﬀeredamildanemiabutmaintainedbonemarrowactivity,
as the CHr values state (30.8 and 31.6pg, resp.). RSf values
in these patients were in the reference range of RSf, but the
macrocytosis associated to CKD and hemodialysis treatment
causes that 15% of the patients in this group had RSf values
slightly over the reference range, 106.6fL.
Diagnostic sensitivity, speciﬁcity, and eﬃciency of RSf
were good when compared to a 28pg value of CHr. In
particular, a cutoﬀ value of 91.1fL for RSf showed the
best diagnostic eﬃciency, with a sensitivity of 98.8% and a
speciﬁcity of 89.6%.
This study shows a reasonable agreement between %
Hypo and LHD% and their values showed the same trend
in the diﬀerent groups.
%Hypo values in patients undergoing therapy were near
thethresholdofirondeﬁcienterythropoiesis5%(ACD4.1%,
CKD 5.1%).
The LHD% values obtained in these groups of patients
were statistically lower (ACD 7.3%, CKD 9.6%) than the
iron deﬁcient ones (29.6%, 27.3%) but, as all of them had
a mild anemia, LHD% values in these patients were above
the reference range 4.4%.
The optimal cutoﬀ point for LHD% was 6.0%, which
provided sensitivity 96.6%, speciﬁcity 83.2%, and area under6 Anemia
curve 0.954, for iron deﬁciency detection, deﬁned by %Hypo
> 5%.
Inthisstudy,ithasbeenstatedthatRSfandLHD%could
be reliable parameters for the study of iron status and the
amount of the supply available for erythropoiesis.
Iron metabolism is a dynamic process which cannot be
deﬁned by one test parameter only. The analysis of these new
parameters can be performed simultaneously in the course
of routine blood counts, with no incremental costs and no
additional needs of more blood sampling. In conjunction
with standard blood cell counts and iron, parameters could
enable the diagnosis to be made rapidly and accurately.
The new parameters derived from Beckman-Coulter
technology seem to be an acceptable alternative to CHr
and %Hypo in the routine practice, with the same clinical
meaning, but more prospective and longitudinal studies are
needed in order to verify the results obtained, to determine
their reliability for clinical purposes or whether the addi-
tional information provided could be used in managing the
iron requirements of patients.
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